Toll Free: 1-888-928-9744

Phynova Group Ltd - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 25 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Phynova Group Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Phynova Group Ltd - Product Pipeline Review - 2014', provides an overview of the Phynova Group Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Phynova Group Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Phynova Group Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Phynova Group Ltd's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Phynova Group Ltd's pipeline products

Reasons to buy

- Evaluate Phynova Group Ltd's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Phynova Group Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Phynova Group Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Phynova Group Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Phynova Group Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Phynova Group Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Phynova Group Ltd Snapshot 4
Phynova Group Ltd Overview 4
Key Information 4
Key Facts 4
Phynova Group Ltd - Research and Development Overview 5
Key Therapeutic Areas 5
Phynova Group Ltd - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Phynova Group Ltd - Pipeline Products Glance 11
Phynova Group Ltd - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Phynova Group Ltd - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phynova Group Ltd - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Phynova Group Ltd - Drug Profiles 14
Melokinex 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
PYN-17 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
PYN-22 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PYN-6 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PYN-8 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Phynova Group Ltd - Pipeline Products by Route of Administration 19
Phynova Group Ltd - Pipeline Products by Molecule Type 20
Phynova Group Ltd - Recent Pipeline Updates 21
Phynova Group Ltd - Dormant Projects 22
Phynova Group Ltd - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25
List of Tables
Phynova Group Ltd, Key Information 4
Phynova Group Ltd, Key Facts 4
Phynova Group Ltd - Pipeline by Indication, 2014 6
Phynova Group Ltd - Pipeline by Stage of Development, 2014 7
Phynova Group Ltd - Monotherapy Products in Pipeline, 2014 8
Phynova Group Ltd - Partnered Products in Pipeline, 2014 9
Phynova Group Ltd - Partnered Products/ Combination Treatment Modalities, 2014 10
Phynova Group Ltd - Phase III, 2014 11
Phynova Group Ltd - Phase II, 2014 12
Phynova Group Ltd - Preclinical, 2014 13
Phynova Group Ltd - Pipeline by Route of Administration, 2014 19
Phynova Group Ltd - Pipeline by Molecule Type, 2014 20
Phynova Group Ltd - Recent Pipeline Updates, 2014 21
Phynova Group Ltd - Dormant Developmental Projects,2014 22
Phynova Group Ltd, Subsidiaries 23 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify